This project has 4 main lines of investigation. Firstly, we are currently undertaking a comprehensive molecular analysis of lung cancer tissues from European Americans and African Americans and building a precision medicine atlas of lung cancer in African Americans. These samples are being analysed for microRNA, coding gene expression, genetics and methylation. The goal of these analyses are to understand whether differences in tumor biology exist in lung cancers from African Americans and European Americans. Understanding such differences could provide clues for etiology, prevention and new treatments. This work extends from an NCI-led GWAS of lung cancer in African Americans. Thirdly, based on previous literature suggesting that the cytokine profile is different in African Americans and European Americans, and ongoing work in European Americans showing that cytokine profiles are very promising risk, diagnostic and prognostic biomarkers, we are investigating whether a specific inflammatory cytokine profile is also associated with the diagnosis and prognosis of lung cancer in European Americans. Finally, as the main causes of the disparities in incidence are unknown, we are also conducting population studies to assess the potential causes.
Ryan, Bríd M (2018) Lung cancer health disparities. Carcinogenesis 39:741-751 |
Houston, Keisha A; Mitchell, Khadijah A; King, Jessica et al. (2018) Histologic Lung Cancer Incidence Rates and Trends Vary by Race/Ethnicity and Residential County. J Thorac Oncol 13:497-509 |
Meaney, Claire L; Zingone, Adriana; Brown, Derek et al. (2017) Identification of serum inflammatory markers as classifiers of lung cancer mortality for stage I adenocarcinoma. Oncotarget 8:40946-40957 |
Ryan, Bríd M (2016) Differential eligibility of African American and European American lung cancer cases using LDCT screening guidelines. BMJ Open Respir Res 3:e000166 |